
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
A. 510(k) Number:
K153538
B. Purpose for Submission:
New Device
C. Measurand:
CMV-Specific MHC Dextramer
D. Type of Test:
Semi-Quantitative Flow Cytometric Assay
E. Applicant:
Immudex ApS
F. Proprietary and Established Names:
Dextramer® CMV Kit
G. Regulatory Information:
1. Regulation section:
21 CFR § 864.5220, Automated differential cell counter
2. Classification:
Class II
3. Product code:
GKZ, Counter, differential cell
4. Panel:
Hematology (81)
Immunology (82)
1

--- Page 2 ---
H. Intended Use:
1. Intended use:
Dextramer® CMV Kit is a semi-quantitative assay intended for the identification and
enumeration of cytomegalovirus (CMV)-specific CD8+ T cells in anticoagulated (Na
Heparin) whole blood specimens by flow cytometry.
Dextramer® CMV Kit is indicated for assessment of CMV-specific immune status and
risk of CMV reactivation in adult human stem cell transplant patients following
immunosuppression and used in conjunction with other laboratory and clinical findings.
The kit cannot be used to measure CMV infection or disease.
The kit is limited to individuals with the following HLA types: A*0101, A*0201,
B*0702, B*0801, B*3501.
2. Indication for use:
Same as Intended Use
3. Special conditions for use statement:
For prescription Use only
4. Special instrument requirements:
Becton Dickinson FACSCanto II flow cytometer using Diva software
I. Device Description:
The Dextramer® CMV Kit comprises nine different CMV Dextramers representing
seven different alleles as well as three antibodies recognizing CD3, CD4, and CD8:
Dextramer reagents:
· HLA-A*0101 PE-labeled dextran, Class I, peptide sequence VTEHDTLLY,
25 tests/0.25 ml
· HLA-A*0201 PE-labeled dextran, Class I, peptide sequence NLVPMVATV,
50 tests/0.50 ml
· HLA-B*0702 PE-labeled dextran, Class I, peptide sequence TPRVTGGGAM,
25 tests/0.25 ml
· HLA-B*0801 PE-labeled dextran, Class I, peptide sequence ELRRKMMYM,
25 tests/0.25 ml
· HLA-B*3501 PE-labeled dextran, Class I, peptide sequence IPSINVHHY,
25 tests/0.25 ml
· Negative control PE-labeled dextran coupled with HLA-B*801 molecules
complexed with nonsense peptide, 150 tests/1.50 ml
2

--- Page 3 ---
Antibodies:
· Anti-CD8/FITC clone SK1 or clone DK25, 2 ml
· Anti-CD3/PerCP clone SK7 or clone UCHT1, 2 ml
· Anti-CD4/PE clone SK3 or clone MT310, 2 ml
Reagents required but not provided:
· FACS Lysing Solution (10X)
· Trucount tubes
· Control Cells
J. Substantial Equivalence Information:
1. Predicate device name:
Beckman Coulter iTAg MHC Tetramer CMV Kit
2. Predicate 510(k) number:
K051122
3. Comparison with predicate:
Similarities
Item Device Predicate
Dextramer CMV Kit iTAg MHC Tetramer CMV
Kit
Intended Use Dextramer® CMV Kit is a The Beckman Coulter iTAg
semi-quantitative assay MHC Tetramer CMV assay is
intended for the identification for the identification and
and enumeration of enumeration of
cytomegalovirus (CMV)- cytomegalovirus (CMV)-
specific CD8+ T cells in specific CD8+ lymphocytes in
anticoagulated (Na Heparin) whole blood by flow
whole blood specimens by cytometry, and the assessment
flow cytometry. of CMV-specific immune
Dextramer® CMV Kit is status and risk of CMV
indicated for assessment of reactivation in
CMV-specific immune status immunosuppressed stem cell
and risk of CMV reactivation transplant recipients. The
in adult human stem cell assay is limited to individuals
transplant patients following with the following HLA
immunosuppression and used types: A*0101, A*0201,
in conjunction with other B*0702, B*0801, B*3501.
laboratory and clinical
findings.
3

[Table 1 on page 3]
	Similarities							
	Item			Device			Predicate	
			Dextramer CMV Kit	Dextramer CMV Kit			iTAg MHC Tetramer CMV	
							Kit	
Intended Use			Dextramer® CMV Kit is a
semi-quantitative assay
intended for the identification
and enumeration of
cytomegalovirus (CMV)-
specific CD8+ T cells in
anticoagulated (Na Heparin)
whole blood specimens by
flow cytometry.
Dextramer® CMV Kit is
indicated for assessment of
CMV-specific immune status
and risk of CMV reactivation
in adult human stem cell
transplant patients following
immunosuppression and used
in conjunction with other
laboratory and clinical
findings.			The Beckman Coulter iTAg
MHC Tetramer CMV assay is
for the identification and
enumeration of
cytomegalovirus (CMV)-
specific CD8+ lymphocytes in
whole blood by flow
cytometry, and the assessment
of CMV-specific immune
status and risk of CMV
reactivation in
immunosuppressed stem cell
transplant recipients. The
assay is limited to individuals
with the following HLA
types: A*0101, A*0201,
B*0702, B*0801, B*3501.		

--- Page 4 ---
Similarities
Item Device Predicate
The kit cannot be used to
measure CMV infection or
disease.
The kit is limited to
individuals with the following
HLA types: A*0101, A*0201,
B*0702, B*0801, B*3501.
Instrumentation Flow Cytometer same
Sample type Whole Blood same
Cell Type detected CMV-specific CD8+ T cells Same
Human T lymphocytes
Same
Fluorochromes Anti-CD8 FITC Anti-CD8 FITC
Anti-CD4 PE Anti CD4 PE
HLA Types (peptide HLA-A*0101 Same
sequence) (VTEHDTLLY)
HLA-A*0201 Same
(NLVPMVATV)
HLA-B*0702 Same
(TPRVTGGGAM)
HLA-B*0801 Same
(ELRRKMMYM)
HLA-B*3501 Same
(IPSINVHHY)
Differences
Item Device Predicate
Fluorochromes Anti-CD3 PerCP Anti-CD3 PC5
Anticoagulant Na Heparin EDTA
MHC Multimer Dextran Streptavidin
backbone
Detection Method Dextramers Tetramers (complexes of
MHC molecules associated
with a CMV specific peptide
sequence)
4

[Table 1 on page 4]
	Similarities							
	Item			Device			Predicate	
			The kit cannot be used to
measure CMV infection or
disease.
The kit is limited to
individuals with the following
HLA types: A*0101, A*0201,
B*0702, B*0801, B*3501.					
Instrumentation			Flow Cytometer			same		
Sample type			Whole Blood			same		
Cell Type detected			CMV-specific CD8+ T cells
Human T lymphocytes			Same
Same		
Fluorochromes			Anti-CD8 FITC
Anti-CD4 PE			Anti-CD8 FITC
Anti CD4 PE		
HLA Types (peptide
sequence)			HLA-A*0101
(VTEHDTLLY)
HLA-A*0201
(NLVPMVATV)
HLA-B*0702
(TPRVTGGGAM)
HLA-B*0801
(ELRRKMMYM)
HLA-B*3501
(IPSINVHHY)			Same
Same
Same
Same
Same		

[Table 2 on page 4]
	Differences							
	Item			Device			Predicate	
Fluorochromes			Anti-CD3 PerCP			Anti-CD3 PC5		
Anticoagulant			Na Heparin			EDTA		
MHC Multimer
backbone			Dextran			Streptavidin		
Detection Method			Dextramers			Tetramers (complexes of
MHC molecules associated
with a CMV specific peptide
sequence)		

--- Page 5 ---
K. Standard/Guidance Document Referenced (if applicable):
1. ISO 14971 Medical Devices-Application of Risk Management to Medical Devices Guidance
for Industry;2007
2. CLSI EP09-A3, Method Comparison and Bias Estimation Using Patient Samples; Third
Edition; Approved Guideline
3. CLSI H3-A6, Procedures for the Collection of Diagnostic Blood Specimens by
Venipuncture; Sixth Edition
4. CLSI H42-A Flow Cytometry: Quality Assurance and Immunophenotyping of Lymphocytes
5. CLSI I/LA26-A, Performance of Single Cell Immune Response Assays; Second
Edition;2013
L. Test Principle:
The Dextramer CMV Kit test involves a two-step procedure followed by analysis by flow
cytometry. Step 1 is the determination of the percentage of CMV-specific CD3+CD8+T
cells in the sample (Tube A). A negative control /PE Dextramer is added to Tube B in place
of the HLA matching CMV Dextramer. Whole Blood sample (Na Heparin) is incubated with
the selected CMV Dextramer matching the HLA-type(S) of the patient in tube A or the
negative control in tube B. If a blood sample is analyzed by more than one CMV Dextramer,
a separate Tube A for each CMV Dextramer is prepared. Anti-CD8/FITC and anti-
CD3/PerCP are added to Tube A and Tube B and then incubated for a second time. After
incubation and red blood cell lysis, the samples are centrifuged, washed in PBS, and
supernatant is poured off. The remaining cell pellets are suspended in a fixing solution and
assayed on a flow cytometer. Step 2 is the determination of the absolute number of
CD3+CD8+ T cells in the sample (Tube C). The same whole blood sample is added to a
TruCOUNT tube. Anti-CD8/FITC, anti-CD4/PE, and anti-CD3/PerCP are added to the tube
and incubated. After incubation and red blood cell lysis, the samples are assayed on a flow
cytometer. In Tube A, the percentage of CMV-specific CD3+CD8+ cells determined by
subset analysis of the CD3+CD8+ cells. In Tube C, the absolute count of CD3+CD8+ T
Cells is calculated. The absolute number of CMV-specific CD3+CD8+ T cells/µL blood is
then determined by mathematical calculations.
M. Performance Characteristics:
Note: All results below met the manufacturer’s pre-specified acceptance criteria.
1. Analytical performance:
a. Precision/Reproducibility:
Within-laboratory reproducibility was performed by two operators for the A*0101,
A*0201, B*0702, B*0801, and B*3501 CMV dextramers using one FACSCanto II flow
cytometer. A panel of three whole blood samples per allele were tested at negative (<1
cell/µL), low (1-7 cells/µ), and high (≥ 7 cells/µL) CMV-Specific CD8+ T cells. Samples
were tested in replicates of ten per operator with a total of 60 values per allele.
5

--- Page 6 ---
Operator 1 Operator 2
CMV T-
HLA-Type cell Level
N
Allele Dextramer cells/µL Dextramer cells/µL
SD %CV SD %CV
Range of Replicates Range of Replicates
Neg 10 0.00 0.00 NC 0.00-0.17 0.05 NC
A*0101 Low 10 4.44−5.86 0.42 8.60 3.82−5.42 0.48 10.27
High 10 27.01−30.92 1.14 3.97 26.13−32.72 1.79 6.22
Neg 10 0.00 0.00 NC 0.00−0.17 0.06 NC
A*0201 Low 10 0.92−1.90 0.26 16.16 1.23−1.94 0.19 12.33
High 10 8.84−11.21 0.67 6.74 8.05−11.14 0.84 8.85
Neg 10 0.00 0.00 NC 0.00−0.09 0.03 NC
B*0702 Low 10 3.47−4.20 0.21 5.33 2.97−3.87 0.28 8.30
High 10 14.81−16.49 0.56 3.61 14.49−16.84 0.92 5.91
Neg 10 0.26−0.58 0.09 NC 0.31−0.55 0.08 NC
B*0801 Low 10 3.76−5.79 0.58 12.15 4.38−6.06 0.54 10.37
High 10 7.23−8.74 0.52 6.47 4.61−8.11 1.00 14.49
Neg 10 0.00 0.00 NC 0.0.0−0.03 0.01 NC
B*3501 Low 10 2.95−4.43 0.44 11.78 2.64−3.89 0.34 9.62
High 10 19.11−23.02 1.29 6.06 16.26−20.85 1.20 6.42
CMV
HLAType Allele CMV Dextramer Mean SD %CV
T cell N
(cells/μl) (cells/μl)
Level
Negative 20 0.02 0.04 NC
A*0101 HLA-A*0101 / VTEHDTLLY / PE Low 20 4.80 0.49 10
High 20 28.7 1.50 5
A*0201 HLA-A*0201 / NLVPMVATV / PE Negative 20 0.03 0.05 NC
6

[Table 1 on page 6]
HLA-Type
Allele	CMV T-
cell Level	N		Operator 1					Operator 2			
			Dextramer cells/µL
Range of Replicates		SD	%CV		Dextramer cells/µL
Range of Replicates		SD	%CV	
A*0101	Neg	10	0.00		0.00	NC		0.00-0.17		0.05	NC	
	Low	10	4.44−5.86		0.42	8.60		3.82−5.42		0.48	10.27	
	High	10	27.01−30.92		1.14	3.97		26.13−32.72		1.79	6.22	
A*0201	Neg	10	0.00		0.00	NC		0.00−0.17		0.06	NC	
	Low	10	0.92−1.90		0.26	16.16		1.23−1.94		0.19	12.33	
	High	10	8.84−11.21		0.67	6.74		8.05−11.14		0.84	8.85	
B*0702	Neg	10	0.00		0.00	NC		0.00−0.09		0.03	NC	
	Low	10	3.47−4.20		0.21	5.33		2.97−3.87		0.28	8.30	
	High	10	14.81−16.49		0.56	3.61		14.49−16.84		0.92	5.91	
B*0801	Neg	10	0.26−0.58		0.09	NC		0.31−0.55		0.08	NC	
	Low	10	3.76−5.79		0.58	12.15		4.38−6.06		0.54	10.37	
	High	10	7.23−8.74		0.52	6.47		4.61−8.11		1.00	14.49	
B*3501	Neg	10	0.00		0.00	NC		0.0.0−0.03		0.01	NC	
	Low	10	2.95−4.43		0.44	11.78		2.64−3.89		0.34	9.62	
	High	10	19.11−23.02		1.29	6.06		16.26−20.85		1.20	6.42	

[Table 2 on page 6]
CMV T-
cell Level


[Table 3 on page 6]
HLA-Type
Allele

[Table 4 on page 6]
Dextramer cells/µL
Range of Replicates

[Table 5 on page 6]
Dextramer cells/µL
Range of Replicates

[Table 6 on page 6]
HLAType Allele	CMV Dextramer	CMV
T cell
Level		N	Mean
(cells/μl)	SD
(cells/μl)	%CV
A*0101	HLA-A*0101 / VTEHDTLLY / PE	Negative		20	0.02	0.04	NC
		Low		20	4.80	0.49	10
		High		20	28.7	1.50	5
A*0201	HLA-A*0201 / NLVPMVATV / PE	Negative		20	0.03	0.05	NC

[Table 7 on page 6]
Mean
(cells/μl)

[Table 8 on page 6]
SD
(cells/μl

--- Page 7 ---
CMV
HLAType Allele CMV Dextramer Mean SD %CV
T cell N
(cells/μl) (cells/μl)
Level
Low 20 1.60 0.23 14
High 20 10.1 0.93 9
Negative 20 0.02 0.03 NC
B*0702 HLA-B*0702 / TPRVTGGGAM / PE Low 20 3.73 0.40 11
High 20 16.2 1.15 7
Negative 20 0.43 0.08 NC
B*0801 HLA-B*0801 / ELRRKMMYM / PE Low 20 5.12 0.61 12
High 20 7.51 1.00 13
Negative 20 0.00 0.01 NC
B*3501 HLA-B*3501 / IPSINVHHY / PE Low 20 3.78 0.44 12
High 20 21.1 2.27 11
%CV was Not Calculated (NC) for negative samples with CMV-Specific T cells of <1
cell/µL
Site-to-site reproducibility was performed at three clinical laboratory sites for the
A*0101, A*0201, B*0702, B*0801, and B*3501 CMV dextramers using the FACSCanto
II flow cytometers. The study included three different operators using three different flow
cytometers with replicates of three performed in one run including samples across
negative (<1 cell/µL), low (1-7 cells/µ), and high (≥ 7 cells/µL) CMV CMV- Specific
CD8+ T cells. Each sample was tested in triplicate using the HLA matched CMV
Dextramer for a total of 43 replicates per allele. Results for each site are provided for
With-in Run imprecision.
Combined results
Within-Run Within-Run Within-Run Total
Sample N Mean Site 1 Site 2 Site 3
SD %CV SD %CV SD %CV SD %CV
A*0101 High 9 15.5 1.31 7 0.49 4 1.59 10 2.76 18
A*0101 Low 9 5.31 0.58 10 0.54 13 0.83 13 0.91 17
A*0101 Low 7 5.64 0.58 11 N/A N/A 0.24 4 0.33 6
A*0101 Low 7 2.44 0.16 6 N/A N/A 0.31 15 0.27 11
7

[Table 1 on page 7]
HLAType Allele	CMV Dextramer		CMV		N	Mean
(cells/μl)	SD
(cells/μl)	%CV
			T cell					
			Level					
		Low			20	1.60	0.23	14
		High			20	10.1	0.93	9
B*0702	HLA-B*0702 / TPRVTGGGAM / PE	Negative			20	0.02	0.03	NC
		Low			20	3.73	0.40	11
		High			20	16.2	1.15	7
B*0801	HLA-B*0801 / ELRRKMMYM / PE	Negative			20	0.43	0.08	NC
		Low			20	5.12	0.61	12
		High			20	7.51	1.00	13
B*3501	HLA-B*3501 / IPSINVHHY / PE	Negative			20	0.00	0.01	NC
		Low			20	3.78	0.44	12
		High			20	21.1	2.27	11

[Table 2 on page 7]
Mean
(cells/μl)

[Table 3 on page 7]
SD
(cells/μl)

[Table 4 on page 7]
										
			Within-Run		Within-Run		Within-Run		Total	
Sample	N	Mean	Site 1		Site 2		Site 3			
										
			SD	%CV	SD	%CV	SD	%CV	SD	%CV
A*0101 High	9	15.5	1.31	7	0.49	4	1.59	10	2.76	18
A*0101 Low	9	5.31	0.58	10	0.54	13	0.83	13	0.91	17
A*0101 Low	7	5.64	0.58	11	N/A	N/A	0.24	4	0.33	6
A*0101 Low	7	2.44	0.16	6	N/A	N/A	0.31	15	0.27	11

--- Page 8 ---
Within-Run Within-Run Within-Run Total
Sample N Mean Site 1 Site 2 Site 3
SD %CV SD %CV SD %CV SD %CV
A*0101 Negative 9 0.01 0.04 NC 0.00 NC 0.00 NC 0.02 NC
A*0201 High 9 16.5 1.66 9 1.02 7 0.19 1 1.29 8
A*0201 Low 7 5.62 0.30 5 N/A N/A 0.33 7 0.55 10
A*0201 Low 9 2.96 0.12 4 0.25 10 0.21 6 0.27 9
A*0201 Negative 9 0.41 0.21 NC 0.05 NC 0.14 NC 0.12 NC
A*0201 Negative 9 0.01 0.01 NC 0.00 NC 0.03 NC 0.01 NC
B*0702 High 8 7.65 0.69 9 0.82 12 0.43 5 0.51 7
B*0702 Low 9 2.63 0.22 10 0.15 6 0.05 2 0.39 15
B*0702 Negative 8 0.00 0.00 NC 0.00 NC 0.00 NC 0.00 NC
B*0801 High 9 9.90 1.02 9 0.40 5 0.95 9 1.789 18
B*0801 Low 7 5.01 0.50 9 N/A N/A 0.28 5 0.67 13
B*0801 Negative 9 0.00 0.00 NC 0.00 NC 0.00 NC 0.00 NC
B*3501 High 8 7.17 1.20 16 0.30 4 0.16 3 0.47 7
B*3501 Low 9 4.43 0.26 6 0.54 14 0.65 13 0.50 11
B*3501 Negative 9 0.00 0.01 NC 0.00 NC 0.00 NC 0.00 NC
N/A: not applicable; sample not run at site
%CV was Not Calculated (NC) for negative samples with CMV-Specific T cells of
<1 cell/µL.
The %CV for within-lab reproducibility ranged between 5% and 14%. The %CV for
site-to-site reproducibility ranged from 6% and 18%.
b. Linearity/assay reportable range:
The assay linear range was determined using five Na Heparin whole blood samples
from stem cell transplant patients representing all five alleles. Serial dilutions of each
specimen with CMV seronegative blood specimens were tested in triplicate using a
FACSCanto II flow cytometer. Results of linearity study are shown below in tables.
8

[Table 1 on page 8]
										
			Within-Run		Within-Run		Within-Run		Total	
Sample	N	Mean	Site 1		Site 2		Site 3			
										
			SD	%CV	SD	%CV	SD	%CV	SD	%CV
A*0101 Negative	9	0.01	0.04	NC	0.00	NC	0.00	NC	0.02	NC
A*0201 High	9	16.5	1.66	9	1.02	7	0.19	1	1.29	8
A*0201 Low	7	5.62	0.30	5	N/A	N/A	0.33	7	0.55	10
A*0201 Low	9	2.96	0.12	4	0.25	10	0.21	6	0.27	9
A*0201 Negative	9	0.41	0.21	NC	0.05	NC	0.14	NC	0.12	NC
A*0201 Negative	9	0.01	0.01	NC	0.00	NC	0.03	NC	0.01	NC
B*0702 High	8	7.65	0.69	9	0.82	12	0.43	5	0.51	7
B*0702 Low	9	2.63	0.22	10	0.15	6	0.05	2	0.39	15
B*0702 Negative	8	0.00	0.00	NC	0.00	NC	0.00	NC	0.00	NC
B*0801 High	9	9.90	1.02	9	0.40	5	0.95	9	1.789	18
B*0801 Low	7	5.01	0.50	9	N/A	N/A	0.28	5	0.67	13
B*0801 Negative	9	0.00	0.00	NC	0.00	NC	0.00	NC	0.00	NC
B*3501 High	8	7.17	1.20	16	0.30	4	0.16	3	0.47	7
B*3501 Low	9	4.43	0.26	6	0.54	14	0.65	13	0.50	11
B*3501 Negative	9	0.00	0.01	NC	0.00	NC	0.00	NC	0.00	NC

--- Page 9 ---
A*0101 A*0201
Dextramer+ Dextramer+ Dextramer+ Dextramer+
Dilutions N % %
Cells/µL Cells/µL Cells/µL Cells/µL
Recovery Recovery
expected actual actual expected
Neat 3 26.33 26.33 100 107.32 107.32 100
1:1.8 3 14.81 14.25 96 60.37 53.29 88
1:3.2 3 8.33 6.89 83 33.96 29.53 87
1:5.7 3 4.69 3.43 73 19.10 16.16 85
1:9.99 3 2.64 2.53 96 10.74 9.64 90
1:17.8 3 1.48 1.13 76 6.04 4.97 82
1:31.6 3 <1 <1 - 3.40 2.99 88
1:56.1 3 <1 <1 - 1.91 1.61 84
1:99.8 3 <1 <1 - 1.08 0.94 87
1:177 3 <1 <1 - <1 <1 -
B*702 B*801
Dextramer+ Dextramer+ Dextramer+ Dextramer+
Dilutions N % %
Cells/µL Cells/µL Cells/µL Cells/µL
Recovery Recovery
expected actual actual expected
Neat 3 46.95 46.95 100 25.85 25.85 100
1:1.8 3 26.41 27.85 105 14.54 19.49 134
1:3.2 3 14.86 15.91 107 8.18 7.62 93
1:5.7 3 8.36 9.43 113 4.60 4.01 87
1:9.99 3 4.70 5.38 114 2.59 2.48 96
1:17.8 3 2.64 3.12 118 1.46 1.28 88
1:31.6 3 1.49 1.98 133 <1 <1 -
1:56.1 3 <1 <1 - <1 <1 -
1:99.8 3 <1 <1 - <1 <1 -
1:177 3 <1 <1 - <1 <1 -
B*3501
Dextramer+ Dextramer+
Dilutions N %
Cells/µL Cells/µL
Recovery
expected actual
Neat 3 19.19 19.19 100
1:1.40 3 13.71 14.45 105
1:1.96 3 9.79 10.59 108
1:2.74 3 6.99 6.59 94
1:3.84 3 5.00 4.92 98
1:5.38 3 3.57 3.60 101
1:7.53 3 2.55 2.37 93
1:10.54 3 1.82 1.69 93
1:14.76 3 1.30 1.04 80
9

[Table 1 on page 9]
Dilutions	N	A*0101			A*0201		
		Dextramer+
Cells/µL
expected	Dextramer+
Cells/µL
actual	%
Recovery	Dextramer+
Cells/µL
actual	Dextramer+
Cells/µL
expected	%
Recovery
Neat	3	26.33	26.33	100	107.32	107.32	100
1:1.8	3	14.81	14.25	96	60.37	53.29	88
1:3.2	3	8.33	6.89	83	33.96	29.53	87
1:5.7	3	4.69	3.43	73	19.10	16.16	85
1:9.99	3	2.64	2.53	96	10.74	9.64	90
1:17.8	3	1.48	1.13	76	6.04	4.97	82
1:31.6	3	<1	<1	-	3.40	2.99	88
1:56.1	3	<1	<1	-	1.91	1.61	84
1:99.8	3	<1	<1	-	1.08	0.94	87
1:177	3	<1	<1	-	<1	<1	-

[Table 2 on page 9]
Dilutions	N	B*702			B*801		
		Dextramer+
Cells/µL
expected	Dextramer+
Cells/µL
actual	%
Recovery	Dextramer+
Cells/µL
actual	Dextramer+
Cells/µL
expected	%
Recovery
Neat	3	46.95	46.95	100	25.85	25.85	100
1:1.8	3	26.41	27.85	105	14.54	19.49	134
1:3.2	3	14.86	15.91	107	8.18	7.62	93
1:5.7	3	8.36	9.43	113	4.60	4.01	87
1:9.99	3	4.70	5.38	114	2.59	2.48	96
1:17.8	3	2.64	3.12	118	1.46	1.28	88
1:31.6	3	1.49	1.98	133	<1	<1	-
1:56.1	3	<1	<1	-	<1	<1	-
1:99.8	3	<1	<1	-	<1	<1	-
1:177	3	<1	<1	-	<1	<1	-

[Table 3 on page 9]
Dilutions	N	B*3501		
		Dextramer+
Cells/µL
expected	Dextramer+
Cells/µL
actual	%
Recovery
Neat	3	19.19	19.19	100
1:1.40	3	13.71	14.45	105
1:1.96	3	9.79	10.59	108
1:2.74	3	6.99	6.59	94
1:3.84	3	5.00	4.92	98
1:5.38	3	3.57	3.60	101
1:7.53	3	2.55	2.37	93
1:10.54	3	1.82	1.69	93
1:14.76	3	1.30	1.04	80

--- Page 10 ---
r Slope 95%CI Intercept 95%CI
A*0101 0.9982 1.02 0.94−1.10 −0.82 −1.90−0.27
A*0201 0.9978 0.98 0.92−1.04 −1.46 −3.99−1.07
B*0702 0.9996 0.99 0.96−1.03 0.84 0.14−1.54
B*0801 0.9794 1.07 0.76−1.38 −0.09 −4.00−3.82
B*3501 0.9982 1.03 0.98−1.09 −0.18 −0.68−0.31
Cell concentrations were tested for linearity up to−107 cells/µL. The assay shows
linearity between 1−107 cells/µL.
Depending on the sample tested, the upper limit of the linear range (determined by
the highest measured concentration for each allele) for the dextramer-positive cells
varied by allele and ranges from 110 cells/µL (A*010) to 19.0 cells/µL for B*3501.
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
Traceability:
There are currently no international reference standards for flow cytometry available.
Stability:
Sample Stability: The Specimen Stability study was performed using blood from four
healthy donors collected in heparin tubes with high, low and negative CMV- specific
CD8+ T cells. Each sample was analyzed in triplicate using the HLA matched CMV
Dextramer from the Dextramer® CMV Kit within 3 hours, 20−22 hours and 44−48
hours post blood draw using a FACSCanto II flow cytometer (Becton Dickinson).
CD3/CD4/CD8 low and high cell controls were used as quality controls for the
determination of the % and absolute numbers of lymphocyte subsets to ensure that the
reagents adhere to the defined criteria during the study. The study supported stability
of blood specimens collected in sodium heparin for up to 44−48 hours prior to
analysis.
A processed-sample is a specimen that is drawn, prepared, and stained with the
protocol for sample preparation before flow cytometric analysis. A processed-sample
stability study was performed using four healthy donors collected in Na-heparin tubes
representing with high, low and negative CMV- specific CD8+ T cells Each sample
was analyzed in triplicate using the HLA matched CMV Dextramer from the
Dextramer® CMV Kit and stored at 2−8°C in the dark prior to flow cytometer
acquisition. Flow cytometer acquisition was performed within 3−6 hours and 20−26
hours post staining using a FACSCanto II flow cytometer (Becton Dickinson).
CD3/CD4/CD8 low and high cell controls were used to QC the determination of the
% and absolute numbers of lymphocyte subsets. Results of the study demonstrated
that processed samples may be stored for up to 24 hours prior to analysis by flow
cytometry.
10

[Table 1 on page 10]
				r			Slope			95%CI			Intercept			95%CI	
A*0101			0.9982			1.02			0.94−1.10			−0.82			−1.90−0.27		
A*0201			0.9978			0.98			0.92−1.04			−1.46			−3.99−1.07		
B*0702			0.9996			0.99			0.96−1.03			0.84			0.14−1.54		
B*0801			0.9794			1.07			0.76−1.38			−0.09			−4.00−3.82		
B*3501			0.9982			1.03			0.98−1.09			−0.18			−0.68−0.31		

--- Page 11 ---
Shelf Life: Stability testing was performed using only the open vial stability which
will represent the open-vial stability as well as the shelf life for the device.
Open/In use Stability: A real-time, open-vial stability study was performed using
three production lots. The functionality of the Dextramer CMV kit was evaluated
using blood samples representing all claimed HLA-types (A*0101, A*0201, B*0702,
B*801, and B*3501) and demonstrated an open-vial stability of 9 months at 2−8°C.
Additional real-time open-vial stability studies are ongoing
d. Detection limit:
Limit of Blank (LoB): Fifty one Na heparin blood specimens from CMV seronegative
stem cell transplant recipients representing five alleles were included in the study.
100% (51/51) were negative and within 0.00−0.06 cells/µL and thus below the
functional assay sensitivity of 1 cell/µL.
Limit of Detection (LoD): Ten Na heparin whole blood specimens from stem cell
transplant recipients representing five alleles were included in the study. Serial
dilutions of each specimen were tested in triplicate for a total of 48 measurements for
each allele. The Limit of Detection (LoD) was determined to be 1 cell/µL.
Limit of Quantitation (LoQ): The Limit of Quantitation (LoQ) (analytical sensitivity)
is 1 cell/µL as determined by the lowest concentration of cells (cells/µL) that can be
determined with a CV% below 20%.
e. Analytical specificity:
98 % (61/62) of CMV seronegative patients have undetectable (<1 cell/µL) CMV-
specific T cells ranging from 0.00−0.25 cells/µL.
Interference: Samples from healthy human donors were selected to represent the five
alleles and to represent negative, low, and high CMV T-cell response. For each test
cell population, three different concentrations of spiked cell were prepared with 1x
(unspiked), 2x (spiked), and 3x (spiked) levels of interfering white blood cell and
normal, middle, and high level of red blood cells. Each sample was tested in three
replicates on the FACSCanto II flow cytometer. There was no significant
interference from the tested cell populations equivalent to 2x normal level for
monocytes (recovery of 91−114% for 2x ), equivalent to 3x normal level for
granulocytes ( recovery of 91−109% for 2x and 100−117% for 3x), equivalent to 3x
normal level for platelets (recovery of 87−104% for 2x and 81−110% for 3x), and
equivalent to 2x normal level for red blood cells (recovery of 91−109% for middle
level and 89−99% for high level).
Cross reactivity with mismatched alleles: No significant cross-reaction was observed
when a sample with an allele that was different than the allele being measured was
used in the analysis.(mismatching Dextramer CMV reagents). All results from
11

--- Page 12 ---
analysis of four blood samples with CMV-specific T cells with HLA mis-matched
CMV dextramers were within 0.00−0.11 cells/µL and thus below the Limit of
Detection of 1 cell/µL.
f. Assay cut-off:
Not applicable
2. Comparison studies:
a. Method comparison with predicate device:
The method comparison was performed according to CLSI Guideline EP09-A3, at
one site using native samples from the intended use (IU) population and spiked
samples on a Becton Dickinson (BD) FACSCanto II flow cytometer. The same set of
patient samples was used to perform the testing of CD3+/CD8+ T-cells and CMV
specific CD8+ T-cells with the iTAg predicate. A total of 133 samples were tested
including CMV-seropositive and seronegative patients for a total of 188
measurements of which 117 have detectable CMV-specific T-cells. For spiked
samples, a Na heparin blood sample containing CMV-specific CD8+ T-cells of
interest was spiked into multiple different CMV-negative Na heparin blood samples
in order to generate 97 unique samples around the cutoff. Spiked samples were used
because native samples from the intended use population with CMV-specific T cells
around the cut-off are rare.
The total number of patient samples for each of the five claimed alleles as well as the
subset with detectable CMV-specific T-cells in parenthesis is listed in the table
below:
Native IU
Samples
Spiked Samples Total
CMV Dextramer (number
with (n) (n)
values > 1
cell/µL)
HLA-A*0101 / VTEHDTLLY / PE 16(5) 26(25) 42(30)
HLA-A*0201 / NLVPMVATV / PE 41(15) 37(34) 78(49)
HLA-B*0701 / TPRVTGGGAM / PE 13(2) 14(14) 27(16)
HLA-B*0801 / ELRRKMMYM / PE 7(2) 10(8) 17(10)
HLA-B3501 / IPSINVHHY / PE 14(5) 10(7) 24(12)
Total 91(29) 97(88) 188(117)
12

[Table 1 on page 12]
CMV Dextramer	Native IU
Samples
(number
with
values > 1
cell/µL)	Spiked Samples
(n)	Total
(n)
HLA-A*0101 / VTEHDTLLY / PE	16(5)	26(25)	42(30)
HLA-A*0201 / NLVPMVATV / PE	41(15)	37(34)	78(49)
HLA-B*0701 / TPRVTGGGAM / PE	13(2)	14(14)	27(16)
HLA-B*0801 / ELRRKMMYM / PE	7(2)	10(8)	17(10)
HLA-B3501 / IPSINVHHY / PE	14(5)	10(7)	24(12)
Total	91(29)	97(88)	188(117)

--- Page 13 ---
The method comparison was evaluated using only samples with CMV-specific T cells
results >1 cell/µL.
Dextramer CMV Kit vs. Predicate iTAg Tetramer
CMV-specific T cells enumeration results with samples of >1 cell/µL
T subset Slope 95% CI Intercept 95% CI r
CD3+CD8+ 0.9840 0.92 to 1.05 −0.4406 -8.47 to 7.59 0.905
CMV-
specific 1.010 0.89 to 1.13 0.39 0.09 to 0.69 0.952
CD8+T-cell
Agreement with predicate: All Samples
Predicate iTAg Tetramer
Method
≥7 cells/µL <7 cells/µL Total
≥7 cells/µL 33 8 41
Test
<7 cells/µL 5 142 147
Dextramer
CMV Kit
Total 38 150 188
Positive Percent Agreement (33/38): 86.8% (95% CI: 71.9−95.6%)
Negative Percent Agreement (142/150): 94.7% (95% CI: 89.8−97.7%)
Agreement with predicate: Samples with CMV-specific T cells of ≥1 cell/µL
Predicate iTAg Tetramer
Method
≥7 cells/µL <7 cells/µL Total
≥7 cells/µL 33 8 41
Test
<7 cells/µL 5 71 76
Dextramer
CMV Kit
Total 38 79 117
Positive Percent Agreement (33/38): 86.8% (95% CI: 71.9−95.6%)
Negative Percent Agreement (71/79): 89.9% (95% CI: 81.0−95.5%)
Sample range for CD3+CD8+ is 2.90−1389 CD3+CD8+ T cells/µL.
Sample range for CMV-specific CD8+ T-cells is 1.01−93.87 CMV-specific CD8+ T
cells/µL.
13

[Table 1 on page 13]
	T subset			Slope			95% CI			Intercept			95% CI			r	
CD3+CD8+			0.9840			0.92 to 1.05			−0.4406			-8.47 to 7.59			0.905		
CMV-
specific
CD8+T-cell			1.010			0.89 to 1.13			0.39			0.09 to 0.69			0.952		

[Table 2 on page 13]
Method		Predicate iTAg Tetramer		
		≥7 cells/µL	<7 cells/µL	Total
Test
Dextramer
CMV Kit	≥7 cells/µL	33	8	41
	<7 cells/µL	5	142	147
	Total	38	150	188

[Table 3 on page 13]
Method		Predicate iTAg Tetramer		
		≥7 cells/µL	<7 cells/µL	Total
Test
Dextramer
CMV Kit	≥7 cells/µL	33	8	41
	<7 cells/µL	5	71	76
	Total	38	79	117

--- Page 14 ---
b. Matrix comparison:
Only Sodium (Na) heparin was used in this new device as well as with the predicate
device.
3. Clinical studies:
a. Clinical Sensitivity:
Not applicable
b. Clinical specificity:
Not applicable
c. Other clinical supportive data (when a. and b. are not applicable):
Risk Assessment:
A prospective study was performed with 120 patients with an allogenic stem cell
transplant (SCT) followed for up to one year for recurrence of CMV infection and
determination of numbers of CMV-specific CD8+ T cells using the CMV Dextramer
Kit. Dextramer analysis was performed pretransplant, at days 30, 100, and 365 and
included the alleles HLA-A*0101, A*0201, B*0702, B*0801, and B*3501. The
Dextramer giving the highest absolute counts at each timepoint for each patient was
used in analysis and evaluation.
In accordance with routine practice Antigenemia tests were performed weekly from
Day 21 and continuing at least until Day 120 or until the patient was off all
immunosuppression.
Relative risk was evaluated based on results at Day 100 from patients that were both
CMV seropositive and reactivated CMV at least one time. Day 100 was determined to
be the best time point to assess recovery. At day 30, 90% of the patients did not have
any measurable CMV-specific T-cells and none of the patients had reactivated CMV.
There were insufficient numbers of patients in the study at day 365 to make a
conclusion about the performance of the device at that time point.
Fewer patients had results at day 365 as compared to day 100 and the patients were
not followed after the last time point.. Five patients that reactivated CMV had no
CMV Dextramer results obtained at day 100 and were excluded from the study.
Fourteen of the remaining 29 patients had one or more CMV reactivations post day
100 (recurrent viremia group) while 15 patients did not develop CMV infection after
day 100 (resolved group). The average number of CMV-specific T cells in the
resolved group was significantly higher (median=47 cells/µL) compared to the group
with recurrent viremia (median=13 cells/µL).
14

--- Page 15 ---
In summary, 19 patients had recovered CMV-specific CD8+ T cell immunity (levels
≥7 cells/µL) at day 100 and 74% (14/19) of these patients did not develop CMV
infection after day 100. Of the remaining patients, that had <7 cells/µL at day 100,
90% (9/10) developed CMV infection after day 100.
CMV seropositive patients that had one or more CMV reactivations
Recurrent CMV Infection
post Day100
No Yes Total
Delayed Recovery
1 9 10
< 7 cells/µL
CMV Specific Rapid Recovery
14 5 19
CD8+ T cells ≥ 7 cells/µL
Total 15 14 29
All samples
Recurrent Viremia
No Yes Total
Delayed Recovery
77 14 91
< 7 cells/µL
CMV Specific Rapid Recovery
9 20 29
CD8+ T cells ≥ 7 cells/µL
Total 86 34** 120***
* Eight samples were excluded from the final analysis due to HLA alleles did not
match the claimed alleles.
** 34 patients developed antigenemia, however five patients were excluded because
they did not have a sample taken at Day 100.
*** 52 patients were excluded for being CMV seronegative and had CMV
seronegative donors
Risk of developing CMV antigenemia after Day 100
Risk is defined as the risk of a patient with less than 7 cells/µL developing CMV
infection post Day 100 compared to a patient with more than 7 cells/ µL.
15

[Table 1 on page 15]
			Recurrent CMV Infection			
			post Day100			
		No		Yes	Total	
CMV Specific
CD8+ T cells	Delayed Recovery
< 7 cells/µL	1		9	10	
	Rapid Recovery
≥ 7 cells/µL	14		5	19	
	Total	15		14	29	

[Table 2 on page 15]
		Recurrent Viremia		
		No	Yes	Total
CMV Specific
CD8+ T cells	Delayed Recovery
< 7 cells/µL	77	14	91
	Rapid Recovery
≥ 7 cells/µL	9	20	29
	Total	86	34**	120***

--- Page 16 ---
Development of antigenemia (post Day 100)
# CMV+ T Yes No Total
cells at Day
100
<7 cells/µL 9 1 10
≥7 cells/µL 5 14 19
Total 14 15 29
Risk 3.4 (95% CI: 1.57 – 7.46)
Dextramer results were evaluated at Day 30, 100, and Day 365 post-transplant. Only
samples collected on day 100 showed significant association between CMV-specific
CD8+ T cells status and development of antigenemia. Results summarized in the table
above show that the relative risk in developing antigenemia is 3.4 (95% CI: 1.57 – 7.46)
for patients with < 7 cells/µL CMV-specific CD8+ T cells determined by the Dextramer
CMV kit, as compared to patients with ≥ 7 cells/µL CMV-specific CD8+ T cells.
4. Clinical cut-off:
CMV dextramer+CD8+ T cells >7 cells/µL at Day 100 post-transplant
5. Expected values/Reference range:
The study to determine the expected reference range of CMV-specific T-cells results
obtained with CMV Dextramers was performed using 55 CMV-seropositive and 62
CMV-seronegative stem cell transplant patients. 98% (61/62) of CMV-seronegative
patients have undetectable (< 1 cell/ µL) CMV-specific T cells ranging from 0.00 – 0.25
cells/µL and 56% (31/55) of CMV seropositive patients have detectable (> 1 cell/ µL)
CMV-specific T-cells ranging from 1.15 – 182 cells/ µL. Samples tested may test
negative for CMV-specific T-cells as the CMV response may be restricted to non-
claimed alleles that are not in the scope of this clearance The CMV Dextramer Kit is
intended for use with five claimed alleles.
N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
O. Conclusion:
1. The submitted information in this premarket notification is complete and supports a
substantial equivalence decision.
16

[Table 1 on page 16]
				Development of antigenemia (post Day 100)					
	# CMV+ T		Yes		No		Total		
	cells at Day								
	100								
<7 cells/µL			9		1		10		
≥7 cells/µL			5		14		19		
Total			14		15		29		
Risk			3.4 (95% CI: 1.57 – 7.46)						